16060-55-2

Basic information

• Product Name: Benzamide, N,3-dihydroxy-
• Synonyms: Benzamide, N,3-dihydroxy-
• CAS NO: 16060-55-2
• Molecular Formula: C₇H₇NO₃
• Molecular Weight: 153.14
• Mol File: 16060-55-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzamide, N,3-dihydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N,3-dihydroxy-(16060-55-2)
• EPA Substance Registry System: Benzamide, N,3-dihydroxy-(16060-55-2)

Safety Data

• Hazardous Substances Data: 16060-55-2(Hazardous Substances Data)

Upstream product

• 19438-10-9 methyl 3-hydroxybenzoate 
• 79678-37-8 methyl 3-(benzyloxy)benzoate 
• 69026-14-8 3-benzyloxybenzoic acid 
• 932380-42-2 N-(benzyloxy)-3-hydroxybenzamide 
• 599-71-3 piloty's acid 
• 100-83-4 meta-hydroxybenzaldehyde 
• 7781-98-8 ethyl-3-hydroxybenzoate 

Relevant articles and documents

Effects of certain arylhydroxamic acids on deoxyribonucleic acid synthesis by Ehrlich ascites tumor cells in vitro.

-

HISTONE LYSINE DEMETHYLASE INHIBITORS

The invention provides a compound which is an iV-oxalylglycine derivative of formula (I): a hydroxamic acid derivative of formula (II): or a heteroaryl derivative of fomula (III): wherein n; Z1; Z2; Y1; Y2; A; p; X1; X2; m; R4; B; R5; R6; R7; R8; R9; X3; R10; R11 and R12 are as defined herein, or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of the human 2-oxoglutarate-dependant JMJD2 subfamily of histone demethylases, in particular JMJD2E. Such inhibitors are useful in changing the epigenetic state of cells resulting in the inhibition / activation of chromatin remodelling, multiple gene activation / deactivation, and in treating cancer and other conditions characterised by undesirable cellular proliferation, and psychiatric disorders including depression.

Inhibitors of the FEZ-1 metallo-β-lactamase

Metallo-β-lactamases (MBLs) catalyze the hydrolysis of β-lactams including penicillins, cephalosporins and carbapenems. Starting from benzohydroxamic acid (1) structure-activity studies led to the identification of selective inhibitors of the FEZ-1 MBL, e.g., 2,5-substituted benzophenone hydroxamic acid 17 has a Ki of 6.1 ± 0.7 μM against the FEZ-1 MBL but does not significantly inhibit the IMP-1, BcII, CphA or L1 MBLs.